Funding round-up: Nowatch, Amili, TILT Biotherapeutics, Lead Pharma and Oxeltis, META Pharmaceuticals

China: META Pharmaceuticals, China’s first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totalling US$15m. Investors include Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital. In combining discoveries in immunometabolism and artificial intelligence (AI), META Pharmaceuticals has built an AI-powered metabolic target discovery platform and aims to develop the next generation of safer and…

You must be a HMI Subscriber to view this content.

Subscribe Now »